10,11,6',7'-tetramethoxy-2'-methyl-emetane | 3281-58-1

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吐根碱生物碱
• 英文名称: 10,11,6',7'-tetramethoxy-2'-methyl-emetane
• 英文别名: 2'-methyl-emetine；10,11,6',7'-Tetramethoxy-2'-methyl-emetan；N-Methyl-emetin；Emetine-Me；(2S,3R,11bS)-2-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
• CAS: 3281-58-1
• 化学式: C₃₀H₄₂N₂O₄
• 分子量: 494.674
• InChiKey: QOSOHKDBVVURGZ-NQCABUFKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  依米丁 、 硫酸二甲酯 在 sodium methylate 作用下， 生成 10,11,6',7'-tetramethoxy-2'-methyl-emetane
  参考文献：
  名称：

  Carr; Pyman, Journal of the Chemical Society, 1914, vol. 105, p. 1599

  摘要：

  DOI：

文献信息

• [EN] FAP-ACTIVATED COMPOUNDS FOR TREATMENT OF CANCER<br/>[FR] COMPOSÉS ACTIVÉS PAR PROTÉINE FAP POUR LE TRAITEMENT DU CANCER
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2022026729A1

  公开（公告）日：2022-02-03

  The present disclosure relates to FAP-activated prodrugs that can be used in the treatment of cancer, such as prostate cancer. The disclosure also relates to pharmaceutical compositions comprising the prodrugs, and related methods of treatment.

  本公开涉及FAP激活的前药，可用于治疗癌症，如前列腺癌。本公开还涉及包含前药的制药组合物以及相关的治疗方法。
• Emetine compounds for treatment and prevention of flavivirus infection
  申请人：FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.

  公开号：US10555942B2

  公开（公告）日：2020-02-11

  The present invention concerns the use of emetine compounds for the treatment or prevention of Flavivirus infections, such as Zika virus infections. Aspects of the invention include methods for treating or preventing Flavivirus virus infection, such as Zika virus infection, by administering an emetine compound such as emetine or cephaeline, or a combination of two or more emetine compounds, to a subject in need thereof; methods for inhibiting Flavivirus infections such as Zika virus infections in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Flavivirus infections, such Zika virus infections.

  本发明涉及使用依美汀化合物治疗或预防弗拉维病毒感染，如寨卡病毒感染。本发明的各个方面包括通过向有需要的受试者施用依美汀化合物，如依美汀或头孢菲林，或两种或多种依美汀化合物的组合物，治疗或预防弗拉维病毒感染，如寨卡病毒感染的方法；在体外或体内抑制细胞中弗拉维病毒感染，如寨卡病毒感染的方法；药物组合物；包装剂型；以及治疗或预防弗拉维病毒感染，如寨卡病毒感染的试剂盒。
• Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US11253511B2

  公开（公告）日：2022-02-22

  The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

  本发明涉及病毒学领域。更具体地说，本发明提供了用于预防和治疗人类巨细胞病毒（CMV）的方法和组合物。在一个实施方案中，药物组合物包含（a）依美汀或其衍生物；（b）人巨细胞病毒（HCMV）药物；以及（c）药学上可接受的载体。在某些实施方案中，药物组合物还包括一种佐剂。在一个具体的实施方案中，HCMV 药物是更昔洛韦。在这种实施方案中，依美汀的用量约为阿米巴病正常用量的 1/10 至 1/100。
• Subbaratnam; Siddiqui, Journal Of Scientific and Industrial Research, 1956, vol. 15 B, p. 432,434
  作者：Subbaratnam、Siddiqui

  DOI：——

  日期：——
• USE OF LOW DOSE EMETINE FOR INHIBITION OF HUMAN CYTOMEGALOVIRUS (HCMV)
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20190022083A1

  公开（公告）日：2019-01-24

  The present invention relates to the field of virology. More specifically, the present invention provides methods and CN compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.